4.7 Article

Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems

期刊

LANCET INFECTIOUS DISEASES
卷 12, 期 11, 页码 888-896

出版社

ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(12)70241-4

关键词

-

资金

  1. Sanofi
  2. Pfizer
  3. Novartis
  4. Sigma Tau
  5. Worldwide Antimalarial Resistance Network through Bill & Melinda Gates Foundation [48807.01]
  6. Wellcome Trust [079080, 092654/Z/10/A]

向作者/读者索取更多资源

Artemisinin-resistant Plasmodium falciparum malaria has emerged in western Cambodia and has been detected in western Thailand. The situation is ominously reminiscent of the emergence of resistance to chloroquine and to sulfadoxine pyrimethamine several decades ago. Artemisinin resistance is a major threat to global public health, with the most severe potential effects in sub-Saharan Africa, where the disease burden is highest and systems for monitoring and containment of resistance are inadequate. The mechanisms that underlie artemisinin resistance are not fully understood. The main phenotypic trait associated with resistance is a substantial delay in parasite clearance, so far reported in southeast Asia but not in Africa. One of the pillars of the WHO global plan for artemisinin resistance containment is to increase monitoring and surveillance. In this Personal View, we propose strategies that should be adopted by malaria-endemic countries in Africa: resource mobilisation to reactivate regional surveillance networks, establishment of baseline parasite clearance profiles to serve as benchmarks to track emerging artemisinin resistance, improved data sharing to allow pooled analyses to identify rare events, modelling of risk factors for drug resistance, and development and validation of new approaches to monitor resistance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据